Survival following lung transplantation for artificial stone silicosis relative to idiopathic pulmonary fibrosis

Dror Rosengarten, Benjamin D. Fox, Elizabeth Fireman, Paul D. Blanc, Victoria Rusanov, Oren Fruchter, Yael Raviv, Osnat Shtraichman, Milton Saute, Mordechai R. Kramer

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Background: Silicosis is a progressive lung disease resulting from the inhalation of respirable crystalline silica. Lung transplantation is the only treatment for end-stage silicosis. The aim of this study was to analyze the survival experience following lung transplantation among patients with silicosis. Methods: We reviewed data for all patients who underwent lung transplantation for silicosis and a matched group undergoing lung transplantation for idiopathic pulmonary fibrosis (IPF) at a single medical center between March 2006 and the end of December 2013. Survival was followed through 2015. Results: A total of 17 lung transplantations were performed for silicosis among 342 lung transplantations (4.9%) during the study period. We observed non-statistically significant survival advantage (hazard ratio 0.6; 95%CI 0.24–1.55) for those undergoing lung transplantation for silicosis relative to IPF patients undergoing lung transplantation during the same period. Conclusions: Within the limits of a small sample, survival in silicosis patients following lung transplantation was not reduced compared to IPF. Am. J. Ind. Med. 60:248–254, 2017.

Original languageEnglish
Pages (from-to)248-254
Number of pages7
JournalAmerican Journal of Industrial Medicine
Volume60
Issue number3
DOIs
StatePublished - 1 Mar 2017
Externally publishedYes

Keywords

  • idiopathic pulmonary fibrosis
  • lung transplantation
  • occupational lung disease
  • silicosis
  • survival

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Fingerprint

Dive into the research topics of 'Survival following lung transplantation for artificial stone silicosis relative to idiopathic pulmonary fibrosis'. Together they form a unique fingerprint.

Cite this